about
Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumabGuillain–Barré SyndromeDiagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosisIdentification of targets and new developments in the treatment of multiple sclerosis--focus on cladribineAtacicept: targeting B cells in multiple sclerosisGenetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisSubcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathiesPredicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic NeuritisAge-dependent modulation of cortical transcriptomes in spinal cord injury and repairNatalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringOral fingolimod or intramuscular interferon for relapsing multiple sclerosisAlemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialCladribine tablets for the treatment of relapsing-remitting multiple sclerosisDisease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responsesRituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneityGuillain-Barré syndrome after exposure to influenza virusQuinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II moleculesPromoting myelination in an in vitro mouse model of the peripheral nervous system: the effect of wine ingredients [corrected]Osteopontin, a macrophage-derived matricellular glycoprotein, inhibits axon outgrowthHistone methyltransferase enhancer of zeste homolog 2 regulates Schwann cell differentiationReassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosisGenome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialPharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in GermanyIn vitro neuronal network activity in NMDA receptor encephalitis.Retinal neurodegeneration in Wilson's disease revealed by spectral domain optical coherence tomography.A comparison of magnetization transfer ratio, magnetization transfer rate, and the native relaxation time of water protons related to relapsing-remitting multiple sclerosis.[Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment, and prognosis]Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis.Acute disseminated encephalomyelitis: an update.Cloning and expression of the Campylobacter jejuni lon gene detected by RNA arbitrarily primed PCR.Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis.Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis.Niche-dependent development of functional neuronal networks from embryonic stem cell-derived neural populations.The role of integrins in immune-mediated diseases of the nervous system.MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.Mechanisms of immune regulation in the peripheral nervous system.
P50
Q21146701-63CFA6CE-648C-424F-AA4C-BD1FB238CCA5Q22248108-6BFB8618-9927-4677-91B3-BF712159BB0DQ22252938-B5C4C238-8EAB-4CDB-9959-1029A805BBFEQ22252943-2E05A94F-6581-477F-8864-F9217D268998Q24597369-91A91C18-8A58-476A-9A0F-E4487EE74900Q24628925-0715FDB2-EE96-4C24-B42F-DAACEE7EEAA9Q24635370-19F93764-8F20-44D2-B5BE-F47CABC7D038Q26745685-87FE151F-C25B-4794-B871-0743C6B3632BQ27320796-2457D02F-718F-4CC0-BDEF-F668B6444355Q27335100-89E12A11-FCB9-4731-93C7-B4BCCF110757Q28243804-2FC9C813-8F05-4318-96CE-FD906F3448ADQ28271008-4883D093-EED9-4766-BB92-591B709D1D48Q28278620-C37B9A44-C388-4CD4-AA36-C78D40C87891Q28281816-0C6314EC-3AD8-43EE-AC7F-30AF337D777FQ28289228-FDBAF6E3-FEB4-42BD-BE2B-07B97DFB6F0BQ28290005-112835AB-B6F0-4959-900A-2D1AD1EAB22AQ28291850-C978762C-D436-47CC-9FDF-8FD6567461E0Q28478607-475BF1D2-EF62-4B02-A563-2E4843859276Q28533740-75A743A5-8F85-4DC3-908D-376C67C2A938Q28570819-648916C6-BBDA-482E-8AF6-A5E688981B76Q28570956-054FB686-E238-483F-B650-B49F1334473BQ28740839-7AA4B477-7003-4C62-A0D5-06305AD87520Q29417047-60F6449A-5B5A-4524-A378-93B41FE0924CQ30053056-180300AD-B0E5-47E5-AF70-12A36E821274Q30250250-0DC83E7B-E59E-4848-B717-F2627D39E02EQ30277106-92FCEEF7-0523-44F7-8E21-E66A1A0502D8Q30362413-45D17790-D710-4BF9-A619-A514966A559EQ30458189-706AB549-0370-4645-A3A8-C0F103E1C0C3Q30460735-87CB8E8F-D2EC-4FAA-B2BE-3193216CC9F5Q30620703-1E69F3DB-B36D-4B42-A3F2-370E5C92F353Q30977770-3002CC55-2867-4423-8754-04623C151415Q31014036-30053811-157D-45A6-8A16-9E8BB544DF14Q31018411-402E2DF0-D69F-41E3-A96C-446A93AEA159Q32019915-454C3607-88A1-44F6-BEFD-2D26F598A46FQ32059017-0637B1BE-5A59-4550-A44A-315B5D5AC295Q32133808-1D74A0CE-849C-48A3-AE04-06E7A083B4B7Q33491268-54F3D0DD-4706-4A28-86BC-2EF10935C4DDQ33544245-22BA3B4A-9F26-4531-9176-66F2DE840BB2Q33571905-DCD59A5B-65F7-49A1-B57A-21F36C2E69B1Q33603460-FADFDB8B-4CBD-4D78-B28F-7D0A490F8BBB
P50
subject
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Hans-Peter Hartung
@ast
Hans-Peter Hartung
@en
Hans-Peter Hartung
@es
Hans-Peter Hartung
@nl
Hans-Peter Hartung
@sl
type
label
Hans-Peter Hartung
@ast
Hans-Peter Hartung
@en
Hans-Peter Hartung
@es
Hans-Peter Hartung
@nl
Hans-Peter Hartung
@sl
prefLabel
Hans-Peter Hartung
@ast
Hans-Peter Hartung
@en
Hans-Peter Hartung
@es
Hans-Peter Hartung
@nl
Hans-Peter Hartung
@sl
P1006
P214
P1006
P101
P106
P21
P214
P31
P496
0000-0002-0614-6989
P734
P7859
lccn-n97801101